Equities research analysts forecast that Henry Schein, Inc. (NASDAQ:HSIC) will post $0.91 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Henry Schein’s earnings. The lowest EPS estimate is $0.90 and the highest is $0.92. Henry Schein posted earnings of $1.12 per share in the same quarter last year, which indicates a negative year over year growth rate of 18.8%. The firm is scheduled to report its next quarterly earnings report before the market opens on Thursday, February 20th.
On average, analysts expect that Henry Schein will report full-year earnings of $3.45 per share for the current financial year, with EPS estimates ranging from $3.44 to $3.46. For the next year, analysts anticipate that the company will report earnings of $3.71 per share, with EPS estimates ranging from $3.66 to $3.75. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Henry Schein.
Several equities research analysts have commented on HSIC shares. Barrington Research restated a “buy” rating and issued a $75.00 price objective on shares of Henry Schein in a research report on Wednesday, November 6th. BidaskClub upgraded Henry Schein from a “hold” rating to a “buy” rating in a research report on Tuesday, January 28th. Evercore ISI lowered Henry Schein from an “in-line” rating to an “underperform” rating in a research report on Friday, January 3rd. Bank of America lowered Henry Schein from a “neutral” rating to an “underperform” rating and set a $65.00 price objective on the stock. in a research report on Thursday, January 9th. Finally, Piper Jaffray Companies upped their price objective on Henry Schein from $72.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Five investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. Henry Schein presently has an average rating of “Hold” and a consensus target price of $70.50.
Henry Schein declared that its Board of Directors has initiated a share repurchase plan on Thursday, October 31st that allows the company to buyback $400.00 million in outstanding shares. This buyback authorization allows the company to buy up to 4.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.
Several large investors have recently made changes to their positions in HSIC. Macquarie Group Ltd. lifted its position in shares of Henry Schein by 29.4% during the 2nd quarter. Macquarie Group Ltd. now owns 4,847 shares of the company’s stock valued at $339,000 after buying an additional 1,100 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in Henry Schein by 11.9% in the 3rd quarter. Pacer Advisors Inc. now owns 30,427 shares of the company’s stock valued at $1,932,000 after purchasing an additional 3,224 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Henry Schein by 19.6% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 9,196 shares of the company’s stock valued at $583,000 after purchasing an additional 1,509 shares in the last quarter. PGGM Investments lifted its holdings in Henry Schein by 52.3% in the 3rd quarter. PGGM Investments now owns 472,712 shares of the company’s stock valued at $30,017,000 after purchasing an additional 162,315 shares in the last quarter. Finally, Schwab Charitable Fund purchased a new position in Henry Schein in the 3rd quarter valued at $208,000.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Story: What sectors are represented in the FTSE 100 index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.